A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

PC14586

First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

DRUG

Itraconazole

Antifungal treatment that is a potent inhibitor of CYP3A4.

Trial Locations (1)

Fortrea, Madison